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Background: For patients with high risk breast cancer and mastectomy, radiotherapy is the treatment of choice to
improve survival and local control. Target dose is mainly limited due to skin reactions. The feasibility of using 4 MV
beams for chest wall treatment was studied and compared to standard 6 MV bolus radiotherapy.
Methods: Post-mastectomy IMRT was planned on an Alderson-phantom using 4 and 6 MV photon beams without/
with a 0.5 cm thick bolus. Dose was measured using TLDs placed at 8 locations in 1 and 3 mm depth to represent
skin and superficial target dose, respectively.
Results: 4 MV and 6 MV beams with bolus perform equally regarding target coverage. The minimum and mean
superficial target dose for the 6 MV and 4 MV were 93.0% and 94.7%, and 93.1% and 94.4%, respectively. Regarding
skin dose the 4 MV photon beam was advantageous. The minimum and mean skin dose for the 6 MV and 4 MV
was 76.7% and 81.6%, and 69.4% and 72.9%, respectively. The TPS was able to predict dose in the build-up region
with a precision of around 5%.
Conclusions: The use of 4 MV photon beams are a good alternative for treating the thoracic wall without the need
to place a bolus on the patient. The main limitation of 4 MV beams is the limited dose rate.Background
For patients with high risk breast cancer and mastec-
tomy, postoperative radiotherapy is the treatment of
choice to improve local control and survival [1-3]. The
2005 Oxford meta-analysis shows that for node positive
patients post-mastectomy radiotherapy (PMRT) decrease
significantly the risk of chest wall recurrence from 21%
to 7.8% and that this improvement is also correlated
with an improvement of survival [3]. Thus, delivering
adequate radiation doses to the chest wall is crucial
to reduce the risk of treatment failure [4]. Keeping
radiation-induced side effects to the skin as low as pos-
sible, while providing the intended dose to the chest wall
remains a challenge [5,6].
Commonly post-mastectomy radiotherapy (PMRT) is
administered using low energy photon beams (usually* Correspondence: uwe.schneider@uzh.ch
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reproduction in any medium, provided the oraround 6 MV) in combination with boluses made from
tissue-equivalent material. The bolus should be thick
enough to provide an adequate dose build-up in the
superficial chest wall, while keeping the dose to the skin
as low as possible. Andic et al. [7] evaluated the optimal
frequency for bolus PMRT and recommended for a typ-
ical treatment of 50 Gy in 25 fractions with 6 MV x-rays
to use the bolus for 15 fractions only.
Another possibility to improve the chest wall dose dis-
tribution for PMRT would be using a photon energy
lower than 6 MV x-rays.
The purpose of the present study is to calculate and
measure skin and target dose distributions in an Alderson
Rando phantom irradiated with 4 MV x-rays without
bolus, and with 6 MV with and without bolus.
Methods
Target definition and treatment planning
An adult anthropomorphic Alderson-Rando phantom
(RSD Radiology Support Devices, Long Beach, CA) wasral Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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that was tissue equivalent for photon beams. A planning
CT study of the phantom with 1.25 mm slice spacing was
performed. The scan geometry is shown in Figure 1. The
external surface of the patient and lung contours were de-
fined with automated density gradient segmentation. The
planning target volume of the chest wall was delineated
according to following anatomical structures: Cranial:
Caudal border of the clavicle head; Caudal: presumed
inframammary fold; Anterior: 3 mm below the skin sur-
face; Posterior: Rib-pleural interface; Lateral: Mid-axillary
line; Medial: Sternal-rib junction. The distance of the PTV
to the skin surface was chosen to be 3 mm since it was
demonstrated that the blood vessels in the skin run within
the first 5 mm under the epiderm (8. 9).
We used for treatment planning the Eclipse External
Beam Planning system version 10.0 (Varian Oncology
Systems, Palo Alto, CA) using the analytic anisotropic
algorithm (AAA, version 10.0.28). Treatment planning
was performed according to the clinical standard at our
institution with two isocentric tangential asymmetric
treatment fields, both intensity modulated (IMRT) for
virtual missing tissue compensation. The field geometry
is shown in Figure 2. Field sizes were 7.7 cm and
14.5 cm in the cranial-caudal direction. Two photon
beams with energies of 4 MV and 6 MV were used. The
planned dose was 2 Gy per fraction with a total dose of
50 Gy. For the 6 MV beam two treatment plans were
computed, one without bolus and one with 0.5 cm bolus
material over the whole irradiation volume. According
to the results of Andic et al. [7], which is the clinical
practice in our institution, the 6 MV bolus treatment
plan was weighted 60% and the non-bolus plan 40% for
dose comparison. The treatment aim was a 95% coverageFigure 1 Illustration of the Alderson phantom with the TLD
measurement positions marked. Please note that the ‘+’-marks are
not relevant for this experiment.of the PTV. Treatment was administered using a Varian
Truebeam linear accelerator with firmware 1.6 with sli-
ding window technology (Varian Medical Systems, Palo
Alto, CA, USA).
Dose measurement
The dose measurements were performed using ther-
moluminescent dosimeters (TLDs) placed inside the
Alderson-Rando phantom without casing (disks with a
diameter of 4.50 mm and a thickness of 0.60 mm). The
trading name of the detectors was TLD-100H (Thermo
Fisher Scientific, Waltham, MA, USA). The useful dose
range of the dosimeters was 1 μGy to 20 Gy according
to the manufacturer.
TLDs were readout with a Fimel PCL3 isothermal TLD
reader (PTW, Freiburg, Germany). A grey filter was ap-
plied during the detector read-out. Background dosi-
meters were used to correct the measurements for
background signal. Reference dosimeters in each batch
corrected for the daily variation in the TLD reader output.
The dosimeters were calibrated using the 6 MV beam of a
Varian Clinac 21 iX (Varian Medical Systems, Palo Alto,
CA, USA) and a RW3 solid water slab phantom (PTW,
Freiburg, Germany). For each TLD, a calibration factor in
terms of dose per reader count was determined. The cali-
bration was metrologically traceable to the Swiss National
Metrology Institute (METAS). The reproducibility of a
single dose measurement was 8% [8]. At each location
measurements were repeated 9 to 11 times which resulted
in a dose error between 2.4% and 2.7%.
A total of 8 measurement positions were selected in the
phantom (Figure 1). A set of four 3 mm deep holes were
drilled into the Alderson phantom in a plane 0.10 cm cra-
nial to the isocenter. As the thickness of one TLD is
0.6 mm, the effective point of measurement for those
TLDs was in 2.7 mm depth. Thus these measurement po-
sitions represented the superficial part of the PTV which
is most critical regarding PTV-under-dosage and are
marked as 3.1 – 3.4 in Figures 1 and 2. A second set of
four holes each 1 mm in depth was drilled 2.65 cm caudal
to the isocenter. The effective measuring depth of
0.7 mm represented the skin dose (marked as O.1 – O.4
in Figure 1). It should be noted that the holes and en-
graved numbers were filled with wax when the phantom
was CT scanned to ensure precise dose calculation on the
planning CT. On the planning CT the TLD positions were
marked to obtain the computed dose at each measure-
ment location. Before irradiation the phantom was posi-
tioned using two orthogonal kV set-up fields. Afterwards
the TLDs were placed into the phantom and irradiated
with one fraction (2 Gy) of the treatment plan. The mea-
surements were repeated 9 to 11 times to reduce the
measurement error. For the measurement, the 3 mm
holes including the TLDs were closed with a plug made
Figure 2 Transversal slice at 0.1 cm cranial to the isocenter with the TLDs (in blue) in 3 mm depth. For the 4 MV treatment plan the 85%,
95%, 100% and 105% isodoses are marked in yellow, orange, green and red, respectively. The geometry of the two tangential fields is shown.
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holes were irradiated open.Results
The prescribed dose of a treatment fraction was 2 Gy.
In Table 1 and Figure 3 the measured dose at the 4 lo-
cations in 3 mm depth is listed as a percentage of the
prescribed dose. The light grey bars in Figure 3 indicate
the results from the 4 MV measurement and the dark
grey bars from the 6 MV measurements without/with
bolus using a 40/60 weighting. In the figure the 95%
dose is indicated by a solid line to show the treatment
aim which was a 95% coverage of the PTV. The mini-
mum and mean dose for the 6 MV treatment approach
was 93.0% and 94.7%, respectively. For 4 MV the mini-
mum and mean dose was 93.1% and 94.4%.Table 1 Results of the TLD measurements at the four
positions in 3 mm depth (3.1 – 3.4) and 1 mm depth
(O.1 – O.4) in percentage of 2 Gy (prescribed dose per
fraction) for the 4 MV and the 6 MV treatment plan









The 6 MV treatment without/with bolus was weighted 40/60.The results of the measurements in 1 mm depth are
listed in Table 1 and plotted in Figure 4. The minimum
and mean dose for the 6 MV treatment approach was
76.7% and 81.6%, respectively. For 4 MV the minimum
and mean dose was 69.4% and 72.9%.
In Table 2 the measured doses in Gy with the corre-
sponding dose error (one standard deviation) is com-
pared to the calculated dose values from Eclipse-AAA.Discussion
PMRT decreases loco-regional recurrence and can in-
crease survival in high-risk breast cancer patients [3].
The American Society of Clinical Oncology has publishedFigure 3 Measured dose at the 4 locations in 3 mm depth as a
percentage of the prescribed dose. The light grey bars indicate the
results from the 4 MV measurement and the dark grey bars from the 6
MV measurements without/with bolus using a 40/60 weighting.
Figure 4 Measured dose at the 4 locations in 1 mm depth as a
percentage of the prescribed dose. The light grey bars indicate the
results from the 4 MV measurement and the dark grey bars from the 6
MV measurements without/with bolus using a 40/60 weighting.
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mal technique for PMRT remains unknown.
Skin in itself may not be part of the clinical target vol-
ume (CTV) since recurrence on the skin scar is a rare
event [9]. On the other hand the work from Van Limber-
gen in breast brachytherapy showed the importance avoid-
ing the terminal branches of the skin microvessel that lay
3 mm below the skin surface [10]. So we excluded the first
3 mm of the skin surface from our CTV definition.
An underdosage of the most superficial part of the
PTV is observed with 6 MV irradiation without bolus
due to a larger build-up effect. This can be counterba-
lanced by an artificial tissue, so-called bolus. Its use en-
hances superficial dose, but also skin toxicity. On the
other hand this might impact also local failure.
In 2004, an e-mail survey was sent to all active physician
members of the American Society for Therapeutic
Radiology and Oncology, the Canadian Association of
Radiation Oncologists and the European Society for
Therapeutic Radiology and Oncology. The survey fo-
cused on the technical details regarding the use of aTable 2 Results of the TLD measurements and TPS calculation
and 1 mm depth (O.1 – O.4) in Gy for the 4 MV and the 6 MV
Position 4MV
Measured dose ± error/Gy Computed dose/Gy Difference
O.1 1.39 ± 0.03 1.41 1.4
O.2 1.41 ± 0.03 1.38 −2.1
O.3 1.46 ± 0.03 1.42 −2.7
O.4 1.57 ± 0.02 1.55 −1.3
3.1 1.90 ± 0.04 1.87 −1.6
3.2 1.89 ± 0.03 1.88 −0.5
3.3 1.86 ± 0.05 1.88 1.1
3.4 1.90 ± 0.06 1.95 2.6
The 6 MV treatment without/with bolus was weighted 40/60. The last column indicbolus in PMRT. The results have been published re-
cently [11]. In total, 1035 responses were obtained: 642
from the Americas (568 from the USA), 327 from Europe
and 66 from Australasia. Respondents from the Americas
were significantly more likely to always use a bolus (82%)
than the Europeans (31%), as were the Australasians (65%)
(P < 0.0001). The results also showed wide variation in the
schedule of application (every day [33%] and alternate
days [46%]) and thickness used (< 1 cm [35%] and > or =
1 cm [48%]). There is a wide variation in the use of a bolus
in PMRT, and this probably translates into a variation in
the dose delivered to the skin and may have an effect on
local recurrence. No data are available about a possible
impact of the use of a bolus and local failure.
The measurements performed in this work are an in-
dicator that PMRT with 4 MV beams is equally good as
the optimized [7] bolus/non-bolus (40/60) schedule with
6 MV photon beams when target coverage is important.
With regard to skin sparing the 4 MV treatment is even
advantageous reducing skin dose by about 10% of the
prescribed dose. Another feasibility study was performed
by Petoukhova et al. [12] for head and neck cancers.
They found no significant difference between 4 MV and
6 MV radiation beams with regard to dose in and
around air cavities.
The measured dose in the build-up region was also
compared to the calculations of the Eclipse AAA algo-
rithm. It was found that the precision of the computed
dose is around 5%.
Taking the results of this work into account the use of
4 MV photon beams is advantageous to 6 MV with
bolus. First, a dose distribution of the same quality can
be administered to the PTV, while the use of 4 MV re-
sults in better skin sparing. Second, with 4 MV only one
treatment plan must be computed instead of two with 6
MV, one without and one with bolus. Finally, no bolus
must be placed on the patient which diminishes the po-
tential of for getting the bolus for irradiation.s at the four positions in 3 mm depth (3.1 – 3.4)
(without flab) treatment plan
6MV
/% Measured dose ± error/Gy Computed dose/Gy Difference/%
1.23 ± 0.01 1.23 0.0
1.16 ± 0.01 1.25 7.8
1.35 ± 0.01 1.35 0.0
1.30 ± 0.02 1.37 5.4
1.73 ± 0.01 1.64 −5.2
1.78 ± 0.02 1.71 −3.9
1.81 ± 0.02 1.74 −3.9
1.74 ± 0.02 1.83 5.2
ates the difference between calculation and measurement.
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beams for PMRT. In this work a Varian linear acce-
lerator was used with limited dose-rate of 2.5 Gy/min at
4 MV. The dose-rate is 2.5 times lower than of the 6
MV beam resulting in longer irradiation times. This could
be an additional problem when the deep-inspiration
breath-hold technique, which is standard in our insti-
tution for left-sided breast cancer patients, is used. A
further disadvantage can be the quality of the dose dis-
tribution of two tangential fields with large diameter
targets. 4 MV photons may have worse quality of dose
distribution in two tangential fields covering large
diameter targets.
Conclusions
Detailed skin and target dose measurements of 4 MV
and 6 MV photon beams for post-mastectomy radiother-
apy indicate that 4 MV beams are a good alternative for
treating the thoracic wall without the need to place a
bolus on the patient. Regarding skin dose the 4 MV
beam performed even better than a 6 MV beam with
40/60 bolus schedule. It could be also shown that the
treatment planning system Eclipse with the AAA algo-
rithm was able to predict dose in the build-up region
with a precision of around 5%. The clinical use of 4 MV
beams to treat post-mastectomy patients is a question of
technical issues. The main limitation is the limited dose
rate which is at 4 MV 2.5 times smaller than at 6 MV.
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